Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Zanubrutinib: First Approval

(2020) Yahiya Y. Syed   DRUGS

Current and future role of fedratinib in the treatment of myelofibrosis

(2020) Monica Ragheb et al.   Future Oncology

Management of myelofibrosis after ruxolitinib failure

(2020) Claire N Harrison et al.   ANNALS OF HEMATOLOGY

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

(2020) Steven P. Treon et al.   BLOOD

PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma

(2020) Vladimir Sapon-Cousineau et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 + T cells

(2020) Connor J. Dwyer et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

(2020) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias

(2020) Robert Roskoski   PHARMACOLOGICAL RESEARCH

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19

(2020) Francesca Romana Spinelli et al.   Science Immunology

Pharmaco-Immunomodulatory Therapy in COVID-19

(2020) John G. Rizk et al.   DRUGS

The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy

(2020) Gabriela Pavlasova et al.   HAEMATOLOGICA

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

(2020) F. La Rosée et al.   LEUKEMIA

Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response

(2020) Lucas Leite Cunha et al.   Frontiers in Immunology

Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19

(2020) Magdalena Massalska et al.   Cells

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

(2020) Mark Roschewski et al.   Science Immunology

The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells

(2020) Kamira Maharaj et al.   Blood Advances

Targeting FLT3 mutations in AML: review of current knowledge and evidence

(2019) Naval Daver et al.   LEUKEMIA

Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies

(2019) Fiona H Tan et al.   OncoTargets and Therapy

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program

(2019) James B. Bussel et al.   AMERICAN JOURNAL OF HEMATOLOGY

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages

(2019) Antonin Papin et al.   LEUKEMIA

Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells

(2019) Renuka V. Iyer et al.   Cancers

Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma

(2019) Krish Patel et al.   BLOOD

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types

(2019) Muntasir M. Majumder et al.   HAEMATOLOGICA

The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

(2019) Yi‐Xin Zou et al.   HEMATOLOGICAL ONCOLOGY

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia

(2019) Tom Hofland et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes

(2019) Tom Hofland et al.   JOURNAL OF IMMUNOLOGY

JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation

(2019) Dagmar Gotthardt et al.   Frontiers in Immunology

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia

(2019) Bartosz Puła et al.   Cancers

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL

(2019) Maissa Mhibik et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment

(2019) Alessandro Prezzo et al.   LEUKEMIA RESEARCH

Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study

(2018) Elena Marinelli Busilacchi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity

(2018) Jasper Rip et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model

(2018) Tetsuya Yoshimoto et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

(2018) Jeanne M. Sisk et al.   JOURNAL OF GENERAL VIROLOGY

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

(2018) Howard A Burris et al.   LANCET ONCOLOGY

Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia

(2018) Christopher Pleyer et al.   LEUKEMIA & LYMPHOMA

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

(2018) Qinlian Jiao et al.   Molecular Cancer

Role of Bruton’s tyrosine kinase in B cells and malignancies

(2018) Simar Pal Singh et al.   Molecular Cancer

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses

(2018) Astrid Alflen et al.   Scientific Reports

Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

(2018) Jan A. Burger et al.   BLOOD

Nilotinib in the treatment of chronic myeloid leukemia

(2018) Tomasz Sacha et al.   Future Oncology

Flt3 inhibition alleviates chronic kidney disease by suppressing CD103+ dendritic cell-mediated T cell activation

(2018) Ruifeng Wang et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia

(2018) Lucas Gutierrez et al.   Scientific Reports

The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis

(2017) Panagiotis Tsapogas et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

(2017) Hanna L. M. Rajala et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Ibrutinib treatment improves T cell number and function in CLL patients

(2017) Meixiao Long et al.   JOURNAL OF CLINICAL INVESTIGATION

Syk inhibitors in clinical development for hematological malignancies

(2017) Delong Liu et al.   Journal of Hematology & Oncology

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

(2017) Maria Larrosa-Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity

(2017) Alexander N. R. Weber et al.   Frontiers in Immunology

The PI3K/AKT Pathway as a Target for Cancer Treatment

(2016) Ingrid A. Mayer et al.   Annual Review of Medicine

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

(2016) B. L. Lampson et al.   BLOOD

The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients

(2016) Ana Colado et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

(2016) Laurent Beziaud et al.   CANCER RESEARCH

The development, safety and efficacy of pacritinib for the treatment of myelofibrosis

(2016) Tania Jain et al.   Expert Review of Anticancer Therapy

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade

(2016) Shane A. Curran et al.   Cancer Immunology Research

A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells

(2016) Gayathri Natarajan et al.   OncoImmunology

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

(2016) Clare Sun et al.   JAMA Oncology

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

(2015) C. Sun et al.   BLOOD

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms

(2015) Kathrin Schönberg et al.   CANCER RESEARCH

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis

(2015) A Pardanani et al.   Blood Cancer Journal

Immunological Consequences of JAK Inhibition: Friend or Foe?

(2015) Donal P. McLornan et al.   Current Hematologic Malignancy Reports

Temsirolimus induces surfactant lipid accumulation and lung inflammation in mice

(2014) Satoshi Washino et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis

(2014) Jason Kindrachuk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function

(2014) D. Wolleschak et al.   HAEMATOLOGICA

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

(2014) F. D. Roit et al.   HAEMATOLOGICA

Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease

(2014) Doanh Le Huu et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors

(2014) N. Larmonier et al.   JOURNAL OF IMMUNOLOGY

Spleen Tyrosine Kinase Inhibition Attenuates Autoantibody Production and Reverses Experimental Autoimmune GN

(2014) S. P. McAdoo et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells

(2013) Martin Franz Sprinzl et al.   HEPATOLOGY

Neutrophil cell surface receptors and their intracellular signal transduction pathways

(2013) Krisztina Futosi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

c-Abl tyrosine kinase plays a critical role in β2 integrin-dependent neutrophil migration by regulating Vav1 activity

(2013) Haibin Tong et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The tyrosine kinase Abl is a component of macrophage podosomes and is required for podosome formation and function

(2012) Anna Baruzzi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

JAK and Src tyrosine kinase signaling in asthma

(2012) Kavita Tundwal   Frontiers in Bioscience-Landmark

Tyrosine Kinase Btk Is Required for NK Cell Activation

(2012) Yan Bao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10-Mediated Feedback

(2012) M. J. Pattison et al.   JOURNAL OF IMMUNOLOGY

Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib

(2012) Yoshiki Hayashi et al.   LEUKEMIA & LYMPHOMA

Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies

(2012) Kamal D. Puri et al.   Frontiers in Immunology

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

T cell survival and function requires the c-Abl tyrosine kinase

(2011) Isabelle Silberman et al.   CELL CYCLE

The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers

(2011) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Immunomodulatory effects of anti-angiogenic drugs

(2011) A Heine et al.   LEUKEMIA

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

(2010) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia

(2010) K. Fiedler et al.   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Overview of the immune response

(2010) David D. Chaplin   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Therapeutic Targeting of Syk in Autoimmune Diabetes

(2010) L. Colonna et al.   JOURNAL OF IMMUNOLOGY

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

(2010) Taro Kawai et al.   NATURE IMMUNOLOGY

Midostaurin (PKC412) modulates differentiation and maturation of human myeloid dendritic cells

(2010) Yu-Chuen Huang et al.   TOXICOLOGY IN VITRO

c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration

(2009) Anna Baruzzi et al.   FEBS LETTERS

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications

(2008) T Weichhart et al.   ANNALS OF THE RHEUMATIC DISEASES

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH